JERUSALEM, Israel--(BUSINESS WIRE)--BioLineRx Ltd. (TASE:BLRX), Israel’s leading drug development company, announced today that data from pre-clinical trials of BL-1040, a resorbable implant to treat acute myocardial infarction, was presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, D.C. The pre-clinical data demonstrate that BL-1040 is effective in improving cardiac function and preventing the deterioration of myocardium post myocardial infarction (MI), in pigs. Professor Jonathan Leor, MD, Director of the Neufeld Cardiac Research Institute at Sheba Medical Center in Israel, presented the findings.
